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Abstract
Background: Isolated cases of pulmonary arterial hypertension (PAH) with interferon α or β therapy have been
reported, but no population-based estimates of the incidence of the disease after interferon exposure are available.
The aim of this study was to determine the incidence of PAH after initiation of interferon therapy, using a large
commercial insurance database.
Methods: Using National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes,
we utilized the Clinformatics™ Data Mart (CDM) database to identify subjects between 20 and 65 years old who
received α or β interferon therapy between April 2001 and December 2012. Patients were followed from one year
prior to the first medication claim for interferon to the first diagnosis of pulmonary hypertension using ICD-9-CM
codes 416.0 and 416.8, or disenrollment. In those subjects diagnosed with pulmonary hypertension, a prescription
for PAH-specific medications was used as a surrogate endpoint.
Results: We identified 20,113 subjects who received interferon therapy during the study period. The median
follow-up was 20 months. Pulmonary hypertension occurred in 71 subjects, and PAH-specific medications were
prescribed to 7 of these subjects.
Conclusion: Although our analysis showed that the development of PAH is a rare event with interferon therapy,
the risk of developing the disease is several fold higher than that for the general population.
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Background
In the last quarter of the 20th century, type I interferons,
including α and β, were introduced as treatment for ma-
lignancies, chronic viral infections, and chronic neuro-
logic conditions [1, 2]. Type I interferons are a family of
glycoproteins with potent antiviral, immunomodulatory,
and antitumor properties that are naturally generated in
the human body, in response to pathogens and tumor
cells. Consequently, interferon α was evaluated for the
treatment of chronic hepatitis C with reports of sustained
virologic response with prevention of further hepatic fi-
brosis and progressive organ failure [3–5]. In the manage-
ment of relapsing multiple sclerosis, interferon β has been
reported to decrease relapse rates and reduce disease
burden when assessed by brain imaging [6, 7].
Although the benefits of interferon therapy are well
documented, this medication has several side effects. It
is commonly associated with flu-like illness and less often
with neuropsychiatric effects (depression) and myelosup-
pression (pancytopenia). Occurrence of these side effects
leads to dose reduction or delays in subsequent treatment
and often resolve with drug discontinuation. Pulmonary
arterial hypertension (PAH), a rare but serious side effect
of interferon therapy, was first reported in a patient
with renal cancer [8]. As the indications for interferon
expanded to include chronic hepatitis and multiple
sclerosis, the frequency of reported cases of PAH in-
creased [9–19]. Hence, a consensus group of experts
categorized interferon α and β as medications as pos-
sible risk factors for the development of PAH [20]. To
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investigate this association further, we developed a
study with the aim of determining the incidence of
PAH in a national population of patients living in the
USA who were treated with α and β interferon therapy.
Methods
Study design and data source
This retrospective cohort study was conducted using the
Clinformatics™ Data Mart (CDM) Database (OptumInsight,
Eden Prairie, Minnesota, USA), which contains data on 53
million private insurance enrollees in the USA. The data-
base contains medical claims, pharmacy claims, and admin-
istrative data (member file) for the enrollees. Because our
study was a secondary data analysis, it was classified as ex-
empt research by the University of Texas Medical Branch
Institutional Review Board (IRB).
Study cohort
We initially identified subjects who were started on inter-
feron α or β treatment between April 2001 and December
2012 (Fig. 1). From this cohort, we selected subjects with
continuous enrollment in the prior year. We then selected
those between 20 and 65 years old at treatment initi-
ation. Finally, we identified subjects diagnosed with
multiple sclerosis or hepatitis C in the 3 months before
the start of interferon treatment. We excluded subjects
with a prior diagnosis of pulmonary hypertension. We
used International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9-CM) codes to identify
patients with multiple sclerosis (340), hepatitis C (070.41,
070.44, 070.51, 070.54, 070.70, and 070.71), and pulmon-
ary hypertension (416.0 and 416.8), respectively. Inter-
feron treatment was identified using National Drug Codes
(NDCs) and Healthcare Common Procedure Coding
System (HCPCS) codes J1825, J1826, J1830, J9212,
J9213, J9214, J9215, J9216, Q3025, Q3026, S0145,
S0146, and S0148. NDCs for interferons were identified
with use of the RED BOOK™ drug database (Truven
Health Analytics Inc., Ann Arbor, Michigan, USA).
Measures
Age, gender, region, and follow-up time were obtained
from the member file. We used claims for medical ser-
vices in the year prior to interferon initiation to determine
comorbidities, including connective tissue disorders, liver
disease other than hepatitis C, HIV/AIDS, obesity, hyper-
tension, congestive heart failure, valvular heart disease,
chronic pulmonary disease, diabetes, and sleep apnea
(Appendix).
Outcomes
The primary outcome of interest was PAH, defined as
new initiation of PAH-specific therapies following
interferon therapy. The occurrence of pulmonary
hypertension was identified as the first ICD-9-CM
code (416.0 or 416.8) registered following interferon
therapy. Among those who developed the condition,
we determined whether or not they received PAH-
specific therapy, including ambrisentan, bosentan, epo-
prostenol, iloprost, macitentan, riociguat, sildenafil, tadala-
fil, and treprostinil. These medications were identified
using NDCs and HCPCS codes J1325, Q4080, Q4074,
J3285, Q4077, J7686, S0114, and S0090.
Statistical analysis
We determined the number and proportion of study
subjects with each of the aforementioned measures.
We then estimated the percent of subjects developing
pulmonary hypertension by the Kaplan-Meier method
and presented the result in graphics. Among those
Fig. 1 Cohort selection in patients treated with alpha or
beta interferons
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with a diagnosis of pulmonary hypertension, we esti-
mated the proportion of subjects receiving PAH-
specific medications by the Kaplan-Meier method.
Cox proportional hazards regression was used to
examine the factors associated with pulmonary hyper-
tension. All statistical analyses were performed using
SAS version 9.3 (SAS Inc., Cary, North Carolina,
USA). The significance level was set at 0.05.
Results
We identified 20,113 subjects treated with interferon
therapy for either hepatitis C or multiple sclerosis
between April 2001 and December 2012 (Fig. 1). Ap-
proximately two-thirds of the patients treated with
interferon α or β had hepatitis C (Table 1). Mean age
was 46.4 ± 9.2 years, and the majority of the patients
were between 40 and 59 years old. Gender distribution
was similar. Common comorbid conditions included
hypertension and diabetes observed in 18 and 8%, re-
spectively. Other chronic liver conditions were re-
corded in 13% of the group and included concomitant
hepatitis B and alcohol-related liver disease. One in five
patients on interferon therapy had at least one of the
following cardiovascular conditions: hypertension, con-
gestive heart failure, valvular heart disease, and atrial
fibrillation. Other conditions associated with pulmon-
ary hypertension—such as chronic lung disease, ob-
structive sleep apnea, connective tissue disorders, and
HIV/AIDS—were less common. The median follow-up
time was 20 months (mean 29.49 ± 27.41).
A total of 71 patients developed pulmonary hyperten-
sion during the study period, including 60 with hepa-
titis C and 11 with multiple sclerosis. The mean age for
this group was 52.4 ± 33.5 years, with males comprising
57.7% of the cohort. Common comorbidities included
chronic liver disease other than hepatitis C (42.3%),
hypertension (33.8%), and diabetes mellitus (22.5%).
The mean follow-up time for this group was 52.2 ±
33.5 months.
Figure 2 presents the time to first diagnosis of pul-
monary hypertension in this cohort, estimated by the
Kaplan-Meier method, after initiation of interferon ther-
apy. At 3, 6, and 9 years of follow-up time, 0.36, 0.86, and
1.77% of patients developed pulmonary hypertension, re-
spectively. Table 2 shows the factors associated with the
development of pulmonary hypertension based on Cox
proportional hazards regression. The odds ratio (OR) of
developing pulmonary hypertension was 4.32 (95% CI
1.71–10.96) in patients with connective tissue disorders.
Additional conditions associated with development of
pulmonary hypertension included other liver disease
excluding hepatitis C (OR 3.21; 95% CI 1.93–5.34),
valvular heart disease (OR 3.76; 95% CI 1.16–12.21),
and diabetes (OR 2.27; 95% CI 1.25–4.11).
Among the 71 patients who developed pulmonary
hypertension, 7 were treated with PAH-specific therapies,
and 6 out of them were treated within five months from
their diagnosis (Fig. 3). Treatment medications included
sildenafil (n = 4), tadalafil (n = 1), epoprostenol (n = 1),
and inhaled iloprost (n = 1).
Discussion
In this retrospective, administrative claims study of US
patients with hepatitis C and multiple sclerosis treated
with interferon, a new diagnosis of pulmonary hyperten-
sion was recognized in 71 individuals, and 7 patients
were prescribed PAH-specific therapies. At first glance,
the incidence appears low. However, when compared to
Table 1 Baseline characteristics of patients newly initiated on
interferon therapy between 2001 and 2012
Patient characteristics Number Percent
Indication for interferon
Multiple sclerosis 7190 35.75












Other liver diseaseb 2647 13.16
Diabetes 1589 7.90
Chronic pulmonary disease 750 3.73
Sleep apnea 338 1.68
Connective tissue disorder 331 1.65
Obesity 294 1.46
HIV/AIDS 268 1.33
Valvular heart disease 156 0.78
Congestive heart failure 86 0.43
Atrial fibrillation and flutter 74 0.37
Congenital heart disease 8 0.04
Mean ± STD (Median)
Age 46.36 ± 9.24 (48.00)
Follow-up time, months 29.49 ± 27.41 (20.00)
aA patient could have more than one comorbidity. bExcluding hepatitis C
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the baseline risk in a general population, the incidence is
quite substantial. To elaborate, the total person-years in
our study cohort of 20,113 subjects was 49,360.5 person-
years based on the follow-up time. Considering that the
estimated incidence of PAH is 1.1 to 7.6 per million
adults per year [21], we should have observed less than
one PAH case in our study cohort. However, we identi-
fied 7 cases. This suggests that the risk of developing
PAH in patients receiving interferon α or β therapy is
several fold higher than in general population.
Several drugs and toxins have been recognized as risk
factors in the development of PAH and have been cate-
gorized based on the strength of evidence as definite,
likely, possible, and unlikely [20]. Epidemiologic studies
have determined a definite association between appetite
suppressants as well as contaminated rapeseed oil with
the development of PAH [22–24]. A consensus group of
experts reviewed the evidence regarding the risk associ-
ated with development of PAH and designated α and β
interferons as possible risk factors [20]. In support of
this, case reports have described new-onset PAH with
interferon administration for treatment of chronic mye-
logenous leukemia, renal cell cancer, melanoma, chronic
hepatitis, and multiple sclerosis [8–19]. Savale and col-
leagues described patients with newly diagnosed or
worsening PAH associated with interferon therapy, from
the French PAH registry [25]. In their case series, the
majority of patients received interferon for treatment of
chronic hepatitis C and hemodynamic measurements
were performed to confirm the diagnosis. In addition,
the majority of patients carried other risk factors for
PAH, namely portal hypertension and/or HIV infection.
Similarly, our study represents patients with hepatitis C
and multiple sclerosis treated with interferon that devel-
oped pulmonary hypertension and subsequently received
Fig. 2 Time to the first diagnosis of pulmonary hypertension diagnosis after interferon treatment. The percentages of patients diagnosed with
pulmonary hypertension by year 3, 6, and 9 were 0.36, 0.86 and 1.77%, respectively. IFN- interferons; PH- pulmonary hypertension
Table 2 Factors associated with the likelihood of developing
pulmonary hypertension
Patient characteristics Hazard ratio (95% CI)
Indication for interferon
Multiple sclerosis Reference
Hepatitis C 1.43 (0.69, 2.96)
Age
20–29 Reference
30–39 0.26 (0.02, 4.23)
40–49 1.46 (0.19, 11.19)
50–59 2.41 (0.32, 18.29)
60–65 4.05 (0.49, 33.36)
Gender
Male Reference
Female 1.02 (0.62, 1.68)
Comorbidity, Yes vs No
Hypertension 1.43 (0.84, 2.43)
Other liver diseasea 3.21 (1.93, 5.34)
Diabetes 2.27 (1.25, 4.11)
Chronic pulmonary disease 1.92 (0.82, 4.50)
Sleep apnea 1.31 (0.31, 5.56)
Connective tissue disorder 4.32 (1.71, 10.96)
Obesity 0.73 (0.10, 5.51)
HIV/AIDS 2.63 (0.63, 10.89)
Valvular disease 3.76 (1.16, 12.21)
Congestive heart failure 1.10 (0.15, 8.17)
Note: Congenital heart disease and atrial fibrillation and flutter were not
included in the model because there were no events among patients with
such comorbidities. This model was adjusted for the year of the initial
interferon treatment. aDoes not include hepatitis C
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PAH-specific therapies. These reports support the asso-
ciation of α and β interferons in the development of
PAH.
There is a growing body of evidence implicating the
role of inflammation and autoimmunity in the devel-
opment of PAH, and this has produced work examin-
ing the role of interferons in pulmonary vascular
pathology [26, 27]. Endothelin-1 is a well-established
mediator in the pathogenesis of PAH and is overex-
pressed in patients with PAH [28]. Elevated endothelin
was found in patients receiving interferon α therapy
for chronic hepatitis C, and the dependent increase in
serum endothelin levels seen in these patients was re-
lated to interferon and not to the virus [29]. A group
of investigators systematically addressed the role of
interferon in PAH, using in vitro and in vivo experi-
mental models as well as clinical samples from patients
with scleroderma with and without PAH [30]. They
noted that type I interferons induced endothelin-1 re-
lease from human pulmonary artery smooth muscle
cells. Mice lacking functional type I interferon receptor
(IFNAR1−/−) were protected from the effects of hyp-
oxia and development of PAH. When clinical samples
were analyzed, a greater number of scleroderma pa-
tients with PAH had detectable levels of interferons,
along with significantly higher levels of endothelin-1,
when compared to patients without PAH. Apart from
elevated serum levels of interferons and endothelins,
interferon receptor expression was also increased in
lung sections of scleroderma patients with PAH. Thus,
investigators concluded that type I interferons, their
receptors, and downstream mediators are associated
with PAH. Collectively, these reports provide an
underlying mechanism by which type I interferon re-
sults in the development of PAH.
Our study has several limitations. An important limita-
tion concerns the use of ICD-9 codes for the diagnosis
of PAH. Prior investigations have indicated that these
codes do not adequately distinguish PAH from non-PAH
patients [31–33]. To address this issue, we only exam-
ined patients who were treated with PAH-specific ther-
apies, thereby focusing on patients for whom the
treating physician had sufficient evidence to prescribe
PAH-specific therapies. In addition, we identified pa-
tients with continuous enrollment lacking an ICD-9
code diagnosis for pulmonary hypertension in the pre-
ceding one year. While, hemodynamic data were not
available in this database, we believe that a prescription
for PAH-specific therapy indicates a provider’s clinical
diagnosis of PAH. We assume that an ICD code and
subsequent prescription for PAH-specific therapy repre-
sents a “real world” diagnosis of PAH. Another limita-
tion concerns the duration of follow-up. Our data was
extracted from a large insurance claims database, and
enrollees often discontinued their insurance policies
when they switched to different employers who purchase
insurance plans from other insurance carriers. There-
fore, the dropout rate was high. Reports regarding
interferon-induced PAH indicate that onset of the pul-
monary vascular disease process may take up to 5 years,
and our study may underestimate the incidence. Lastly, al-
though our study cohort had several comorbidities that
are independent risk factors for PAH, their prevalence in
the cohort was much less than in general population.
Conclusion
Using an administrative claims database, we found that
the frequency of PAH in interferon-treated hepatitis C
or multiple sclerosis patients was several fold higher
than that for the general US population.
Fig. 3 Time to the first PAH medication after the first diagnosis of pulmonary hypertension. By the end of follow-up, 7 patients received medication, 6
out of them did so within the fifth month. IFN-interferons; PH-pulmonary hypertension
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